Background
Access to an accurate diagnostic test for Buruli ulcer (BU) is a research priority according to the World Health Organization. Nucleic acid amplification of insertion sequence IS2404 by polymerase chain reaction (PCR) is the most sensitive and specific method to detect Mycobacterium ulcerans (M. ulcerans), the causative agent of BU. However, PCR is not always available in endemic communities in Africa due to its cost and technological sophistication. Isothermal DNA amplification systems such as the recombinase polymerase amplification (RPA) have emerged as a molecular diagnostic tool with similar accuracy to PCR but having the advantage of amplifying a template DNA at a constant lower temperature in a shorter time. The aim of this study was to develop RPA for the detection of M. ulcerans and evaluate its use in Buruli ulcer disease.
Methodology and principal findings
A specific fragment of IS2404 of M. ulcerans was amplified within 15 minutes at a constant 42°C using RPA method. The detection limit was 45 copies of IS2404 molecular DNA standard per reaction. The assay was highly specific as all 7 strains of M. ulcerans tested were detected, and no cross reactivity was observed to other mycobacteria or clinically relevant bacteria species. The clinical performance of the M. ulcerans (Mu-RPA) assay was evaluated using DNA extracted from fine needle aspirates or swabs taken from 67 patients in whom BU was suspected and 12 patients with clinically confirmed non-BU lesions. All results were compared to a highly sensitive real-time PCR. The clinical specificity of the Mu-RPA assay was 100% (95% CI, 84–100), whiles the sensitivity was 88% (95% CI, 77–95).
Conclusion
The Mu-RPA assay represents an alternative to PCR, especially in areas with limited infrastructure.
EDCTP Career Development Fellow Dr Virginie Rozot, a research officer at the South African Tuberculosis Vaccine Initiative (SATVI), has been awarded a multi‑year contract under Wellcome Leap’s Delta Tissue (∆T) programme. Her research will investigate how the human immune system responds to Mycobacterium tuberculosis in the thoracic lymph nodes, and why these responses sometimes fail, allowing the bacteria to spread to other organs. The findings are expected to inform future TB vaccine design and vaccination strategies.
Global Health EDCTP3 is now inviting applications for the EDCTP Prizes 2027, recognising outstanding individuals and research teams from Africa and Europe for their achievements in global health research and innovation.
The 2027 edition will award four prize categories, highlighting excellence in scientific leadership, collaborative team research, and gender-balanced scientific contributions. Prize winners will be announced at the EDCTP Forum 2027 in Madrid, Spain. Submissions are open until 2 September 2026.
Global Health EDCTP3 has opened the calls for abstracts, scientific symposia and workshops for the EDCTP Forum 2027, one of the leading global health research events focused on infectious diseases in sub-Saharan Africa. The deadline for submissions is 2 September 2026 at 17:00 (Brussels time).
Under the theme ‘Innovating together for resilient global health', the 13th edition of the EDCTP Forum, taking place from 5-9 April 2027 in Madrid, Spain, will offer researchers, policymakers, funders and implementers the opportunity to showcase their work at a flagship global health event.
The Forum offers a unique platform to share research findings, build partnerships and help shape discussions on global health priorities. Currently, submissions for abstracts, scientific symposia and workshops are open.